To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Palbociclib|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane|DRUG: Fulvestrant
Sponsor: Fondazione Sandro Pitigliani